Bio-Techne Named TD Cowen’s Top SMID-Cap Pick for 2026

Key Facts

Amid a strategic search for value within the healthcare sector, Bio-Techne has emerged as a key focus for institutional investors. Analyst Kyle Boucher from TD Cowen has identified Bio-Techne (TECH) as a prime SMID-cap investment pick for 2026, reiterating a Buy rating with a $65 price target. According to reports, this designation comes despite recent weakness in the stock price, as the firm views the company as fundamentally undervalued at current levels.

The bullish outlook is driven by anticipated market improvements in biotechnology reagents and diagnostics, which are expected to catalyze performance by fiscal year 2027. While the company faces headwinds from recent insider selling and a relatively high valuation multiple, it remains a standout compared to larger peers like Thermo Fisher Scientific. Per market data, the broader biotech sector is showing signs of recovery as demand for specialized diagnostic tools begins to stabilize following a period of post-pandemic adjustment.

Investors should monitor TECH price action following this top-pick designation to see if it can build momentum toward the $65 target. Looking ahead, macro catalysts such as the US 20-Year Bond Auction results may influence sector valuations. Additionally, the Federal Reserve's recent decision to maintain interest rates at 3.75% (as of June 17, 2026) continues to serve as a critical backdrop for growth-oriented SMID-cap stocks.